Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial
- PMID: 40151130
- PMCID: PMC11955750
- DOI: 10.19852/j.cnki.jtcm.2025.02.009
Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial
Abstract
Objective: To evaluate the effect of this plant as adjunctive therapy on Helicobacter pylori (H. pylori) eradication.
Methods: The plant capsules were prepared and their physicochemical properties were assessed. In this clinical trial, 99 patients with H. pylori infection were randomized to receive Salvia mirzayanii Rech. f. & Esfand (S. mirzayanii) or placebo capsules for two weeks. All the patients in both groups received clarithromycin-based triple therapy. Both intention to treat and per protocol analyses were performed. Eradication rates, treatment side effects, and medication compliance were evaluated in both groups.
Results: H. pylori eradication rate of all the randomized participants was 59.59%. The eradication rate of H. pyloriwas significantly higher in S. mirzayanii group compared with that in the placebo group for per protocol analysis (84.62%, P = 0.026) but not for intention to treat one (65.31%, P = 0.252). There were no significant differences between the two groups regarding the frequencies of the medications side effects and the patients with poor compliance.
Conclusion: The use of S. mirzayanii as adjunctive therapy to 14-day clarithromycin-based triple therapy might improve H. pylorieradication rate.
Keywords: Rech. f. & Esfand; clarithromycin-based triple therapy; resistance.
Figures
Similar articles
-
Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial.Helicobacter. 2015 Feb;20(1):71-7. doi: 10.1111/hel.12176. Epub 2014 Dec 11. Helicobacter. 2015. PMID: 25495272 Clinical Trial.
-
Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?Eur J Gastroenterol Hepatol. 2014 Nov;26(11):1202-8. doi: 10.1097/MEG.0000000000000190. Eur J Gastroenterol Hepatol. 2014. PMID: 25171023 Clinical Trial.
-
Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance.Am J Gastroenterol. 2014 Oct;109(10):1595-602. doi: 10.1038/ajg.2014.222. Epub 2014 Aug 5. Am J Gastroenterol. 2014. PMID: 25091062 Clinical Trial.
-
Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.Drugs. 1996 Jan;51(1):161-78. doi: 10.2165/00003495-199651010-00010. Drugs. 1996. PMID: 8741237 Review.
-
Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies.Turk J Gastroenterol. 2019 May;30(5):420-435. doi: 10.5152/tjg.2019.18693. Turk J Gastroenterol. 2019. PMID: 31060997 Free PMC article.
References
-
- Keikha M, Askari P, Ghazvini K, Karbalaei M. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and Meta-analysis. J Glob Antimicrob Resist 2021; 29: 420-9. - PubMed
-
- Zahid R, Akram M, Riaz M, Munir N, Shehzad M. Phytotherapeutic modalities for the management of Helicobacter pylori associated peptic ulcer. Eur J Inflamm 2020; 18: 1-16.
-
- Askari SF, Avan R, Tayarani-Najaran Z, Sahebkar A, Eghbali S. Iranian Salvia species: a phytochemical and pharmacological update. Phytochemistry 2021; 183: 112619. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical